The investigation of symptoms burden and treatment status in patients with bone metastasis

Chinese-German Journal of Clinical Oncology

Volumn 9, Issue 2, 2010, Pages 63-67

  Shi, Zhiyong ^a   Qiu, Hong ^a   Yu, Shiying ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bisphosphates; Bone metastasis; Skeletal related events (SREs); Symptom burden

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; GABAPENTIN; PLACEBO; ZOLEDRONIC ACID;

ADOLESCENT; ADULT; AGED; ANOREXIA; ANXIETY; ARTICLE; BONE METASTASIS; CANCER PAIN; CANCER PATIENT; CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; FATIGUE; FEMALE; HEALTH SURVEY; HUMAN; LONELINESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; QUALITY OF LIFE; QUESTIONNAIRE; RADIOTHERAPY; VOMITING; XEROSTOMIA;

EID: 77953576215     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-010-0009-7     Document Type: Article

References (28)

1. Burkett VS, Cleeland CS. Symptom burden in cancer survivorship. J Cancer Surviv, 2007, 1: 167-175.
2. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer, 2003, 97: 2919-2925.
3. Walsh D, Rybicki L. Symptom clustering in advanced cancer. Support Care Cancer, 2006, 14: 831-836.
4. Chen ML, Tseng HC. Symptom clusters in cancer patients. Support Care Cancer, 2006, 14: 825-830.
5. Chow E, Fan G, Hadi S, et al. Symptom clusters in cancer patients with bone metastases. Support Care Cancer, 2007, 15: 1035-1043.
6. Lipton A, Jun S. RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care, 2008, 2: 197-203.
7. Sabino MA, Mantyh PW. Pathophysiology of bone cancer pain. J Support Oncol, 2005, 3: 15-24.
8. Hofman M, Morrow GR, Roscoe JA, et al. Cancer patients' expectations of experiencing treatment-related side effects: A University of Rochester Cancer Center - Community Clinical Oncology Program study of 938 patients from community practices. Cancer, 2004, 101: 851-857.
9. Schwartz AL, Nail LM, Chen S, et al. Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest, 2000, 18: 11-19.
10. Kangas M, Bovbjerg DH, Montgomery GH. Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol Bull, 2008, 134: 700-741.
11. Lloyd-Williams M, Reeve J, Kissane D. Distress in palliative care patients: developing patient-centred approaches to clinical management. Eur J Cancer, 2008, 44: 1133-1138.
12. Roth AJ, Massie MJ. Anxiety and its management in advanced cancer. Curr Opin Support Palliat Care, 2007, 1: 50-56.
13. Roscoe JA, Kaufman ME, Matteson-Rusby SE, et al. Cancer-related fatigue and sleep disorders. Oncologist, 2007, 1: 35-42.
14. McMillan SC, Tofthagen C, Morgan MA. et al. Relationships among pain, sleep disturbances, and depressive symptoms in outpatients from a comprehensive cancer center. Oncol Nurs Forum, 2008, 35: 603-611.
15. Sateia MJ, Lang BJ. Sleep and cancer: recent developments. Curr Oncol Rep, 2008, 10: 309-318.
16. Theobald DE. Cancer pain, fatigue, distress, and insomnia in cancer patients. Clin Cornerstone, 2004, 6 Suppl 1D: S15-21.
17. Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr, 2007, 37: 16-21.
18. Hadi S, Fan G, Hird AE, et al. Symptom clusters in patients with cancer with metastatic bone pain. J Palliat Med, 2008, 11: 591-600.
19. Kirkova J, Walsh D. Cancer symptom clusters - a dynamic construct. Support Care Cancer, 2007, 15: 1011-1013.
20. World Health Organization. Achieving balance in national opioids control policy-Guidelines for assessment. Geneva: WHO pubulication, 2000: 3-4.
21. Pavlakis N, Schmidt RL, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev, 2005, 3: 1-38.
22. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer, 2008, 113: 1438-1445
23. Olson K, Van Poznak C. Significance and impact of bisphosphonate- induced acute phase responses. J Oncol Pharm Pract, 2007, 13:223-229.
24. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphos- phonates. J Dent Res, 2007, 86: 1022-1033.
25. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of aninternational expert panel. Ann Oncol, 2008, 19: 420-432.
26. Chow E. Update on radiation treatment for cancer pain. Curr Opin Support Palliat Care, 2007, 1: 11-15.
27. Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol, 2007, 25: 1423-1436.
28. Roos DE, Turner SL, O'Brien PC, et al. Trans-Tasman Radiation Oncology Group, TROG 96.05. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiather Oncol, 2005, 75: 54-63.